[Evaluation of the pharmacoeconomic efficacy of prestance in the treatment of hypertensive patients on the basis of the results of the POTENTIAL program]. / Otsenka farmakoekonomicheskoi effektivnosti preparata prestans pri lechenii bol'nykh arterial'noi gipertoniei na osnove rezul'tatov programmy POTENTsIAL.
Ter Arkh
; 88(11): 83-90, 2016.
Article
in Ru
| MEDLINE
| ID: mdl-28005036
ABSTRACT
AIM:
To pharmacoeconomically estimate the use of a fixed-dose combination of perindopril and amlodipine in the treatment of hypertensive patients. MATERIAL ANDMETHODS:
A pharmacoeconomic study was conducted on the basis of the Russian postmarketing observational open program POTENTIAL, which included the estimation of direct and indirect costs associated with the addition of a fixed-dose combination of perindopril and amlodipine to conventional therapy for hypertension in patients who had not achieved adequate blood pressure (BP) control. Cost-difference, cost-effectiveness, and budget-impact analyses were carried out.RESULTS:
The addition of prestance to conventional therapy for hypertension can reduce total costs by 5.-5.8 times, direct costs required to achieve 1% of patients with adequate BP control by 20.5-42.1 times, and direct costs to improve a patient's status by one visual analogue scale score by 1.03-2.11 times. Within a 5-year horizon, the administration of prestance can decrease the cost of therapy for high BP and related strokes by 1.39-1.46 times.CONCLUSION:
Due its high efficacy, prestance (amlodipine + perindopril) is a pharmacoeconomically preferred alternative only to the conventional therapy for hypertension even if the least costly generics are used, in both the short and medium term.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Economics, Pharmaceutical
/
Hypertension
/
Antihypertensive Agents
Type of study:
Evaluation_studies
/
Health_economic_evaluation
Limits:
Humans
Country/Region as subject:
Asia
/
Europa
Language:
Ru
Journal:
Ter Arkh
Year:
2016
Document type:
Article
Affiliation country: